Attenuation of XXXX with @entity19006 versus @entity460 -based @entity1391 binders in haemodialysis: A pilot randomized controlled trial.

@entity1 @entity6 @entity19006 @entity730 @entity79 @entity1391 @entity4959 @entity460 @entity729 @entity65
BACKGROUND: @entity729 ( @entity729 ) contributes to @entity65 in haemodialysis (HD) @entity1 . Few controlled studies have addressed interventions to reduce @entity729 but non- @entity460 -based @entity1391 binders may be beneficial. No published randomized study to date has assessed the effect of @entity19006 (LC) on @entity729 progression. METHODS: We conducted a pilot randomized controlled trial to determine the effect of LC on @entity729 . Forty-five HD @entity1 were randomized to either LC or @entity4959 (CC). Primary outcome was change in aortic @entity729 after 18 months. Secondary outcomes included superficial femoral artery (SFA) @entity729 , @entity79 ( @entity79 ) of lumbar spine and serum markers of mineral metabolism. At baseline, 6 and 18 month computed tomography was performed to measure @entity729 and @entity79 . A random effect linear regression model was performed to assess differences. RESULTS: Thirty @entity1 completed the study (17 LC, 13 CC); baseline median age 58 years, 38% @entity6 , 64% male. Ninety-three per cent had aortic @entity729 at commencement and 87% showed progression. At 18 months, there was significantly less aortic @entity729 progression with LC than CC (adjusted difference -98.1 (-149.4, -46.8) Hounsfield units (HU), P < 0.001). There was also a non-significant reduction with LC in left SFA @entity729 (-25.8 (-67.7, 16.1) HU, P = 0.2) and right SFA @entity729 (-35.9 (-77.8, 5.9) HU, P = 0.09). There was no difference in lumbar spine @entity79 and serum @entity1391 , @entity460 and parathyroid hormone levels between groups. Limitations to the study include small sample size and loss to follow up. CONCLUSIONS: @entity19006 was associated with reduced progression of @entity730 compared with CC in HD @entity1 over 18 months.
